A Phase 3 Trial of Brepocitinib in Dermatomyositis
Ruth Ann Vleugels·Rohit Aggarwal·Alisa N. Femia·M Bubb·M E Luggen·Raquel Marques·Rashmi Maganti·Erin Boh·C. Charles-Schoeman·Floranne C. Ernste·David Fiorentino·Prateek C. Gandiga·Galina Marder·David Fernández·Hector Chinoy·Latisha Heinlen·Aaron R. Mangold·David R. Pearson·Paul N. Mudd·Jiří Vencovský·Jason C. Sluzevich·Kumaraswamy Sivakumar·Matthew D. Cascino·F. Bozán·Anna Haemel·Victoria P. Werth·Michelle S. Min·Yessar M. Hussain·Mazen M. Dimachkie·Griger Zoltan·Stephen Lindsey·Iazsmin Bauer Ventura·Anthony P. Fernandez·Lisa Christopher-Stine·Eun Bong Lee·Katharina S. Shaw·Chung-Yuan Hsu·Julie J. Paik·Elena Schiopu·Tahseen Mozaffar·Oluwakemi Onajin
In adults with dermatomyositis that was resistant to previous therapy, the use of brepocitinib at a dose of 30 mg (but not at a dose of 15 mg) resulted in significant benefits with respect to a composite myositis index, skin disease severity, glucocorticoid tapering, and functional disability. (Funded by Priovant Therapeutics; ClinicalTrials.gov number, NCT05437263.).